Opendata, web and dolomites

ColoFast SIGNED

Developing a Non-Invasive Kit for Early Colorectal Cancer Detection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ColoFast project word cloud

Explore the words cloud of the ColoFast project. It provides you a very rough idea of what is the project "ColoFast" about.

patient    showed    commercialize    amadix    easily    employees    reduce    189m    avings    improvements    treatment    business    regulatory    savings    25    priorities    fulfill    prevented    deaths    18    profitable    detection    worldwide    life    crc    huge    routine    company    decreasing    616m    strategies    diagnosis    biomarkers    cohorts    commercialization    population    look    generation    opportunity    specificity    global    colorectal    benefit    japan    blood    quality    validate    invasive    earlier    41    sensitivity    prospective    2020    services    size    agrees    cancer    majority    market    clinical    2021    patients    hospitals    multiplying    sme    2024    health    unmet    edge    people    programs    approved    acceptance    kit    healthcare    expanding    assisting    screening    2m    give    mortality    rate    profit    colofasttm    reducing    team    colofast    survival    diagnosed    clear    medical    community    care    national    turnover   

Project "ColoFast" data sheet

The following table provides information about the project.

Coordinator
ADVANCED MARKER DISCOVERY SL 

Organization address
address: CALLE ACERA DE RECOLETOS 2 1 B
city: VALLADOLID
postcode: 47004
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.amadix.com/colofast/
 Total cost 2˙817˙154 €
 EC max contribution 2˙817˙154 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADVANCED MARKER DISCOVERY SL ES (VALLADOLID) coordinator 2˙817˙154.00

Map

 Project objective

Colorectal cancer (CRC) represents one of the most important health problems worldwide. Decreasing the mortality rate by CRC in Europe is a clear unmet need today. Medical community agrees that this number of CRC related deaths could be prevented by adequate screening programs for early detection. European authorities look for new strategies to address the clinical need for early diagnosis of CRC that will reduce patient care associated costs. Potential savings would be achieved if CRC patients were diagnosed earlier. The objective of this proposal is to validate and commercialize a novel, non-invasive, simple to use kit (ColoFastTM), regulatory approved for the diagnosis of CRC in blood. It is based on a new generation of leading-edge biomarkers that showed very high sensitivity and specificity for early detection of CRC in two prospective cohorts. The commercialization of the kit will have clear impact in improving survival of patients and reducing mortality by CRC cancer, with significant costsavings for National Health Services. It will be easily implemented in the clinical routine of the majority of European hospitals, with better acceptance of patients. ColoFast represents a significant business opportunity, addressing a clear unmet medical need in a large and expanding target population of 189M people in Europe in 2020, growing at 25%, with a significant global market of €1,616M in Europe, the US and Japan this year. It will have a huge impact on the growth of a SME as Amadix over the next 10 years, multiplying the team size by five in five years (41 employees in 2020). 2M European people will benefit from the test in 2024. Amadix turnover in 2021 will be €18 m, which will give our company a profit of €7 m in 2021. From this year on the company will be profitable. Overall, ColoFast will reduce mortality rate and treatment cost while improving quality of life in a cost-effective way, assisting also to fulfill European priorities for healthcare improvements.

 Deliverables

List of deliverables.
Research data management plan Documents, reports 2020-01-27 14:54:22
1st Dissemination and Communication Plan: Documents, reports 2020-01-27 14:54:22

Take a look to the deliverables list in detail:  detailed list of ColoFast deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COLOFAST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COLOFAST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

PD_Pal (2019)

Palliative care in Parkinson’s disease

Read More